Pooled KEYNOTE data support pembro for elderly patients with NSCLCApril 12, 2019Lung CancerImmuno-oncology
Preclinical findings highlight value of Lynch syndrome for cancer vaccine developmentApril 8, 2019Immuno-oncologyOncologyPulmonology
Higher dose of checkpoint inhibitor every 4 weeks feasible in NSCLCMarch 7, 2019Lung CancerImmuno-oncology
Diet appears to play an important role in response to anti-PD-1 cancer immunotherapyMarch 1, 2019Immuno-oncologyMelanoma
First-line avelumab/axitinib for RCC benefits wide range of patientsFebruary 21, 2019Genitourinary CancerImmuno-oncology
The Use of Immuno-Oncology Treatments in the VA (FULL)February 4, 2019Immuno-oncologyOncologyLung Cancer
Azacitidine-nivolumab combo 'encouraging' in AMLNovember 14, 2018AMLImmuno-oncologyHematologic Malignancies
Checkpoint inhibitor doubles 3-year survival rate of BRAF wild-type advanced melanomaOctober 25, 2018Immuno-oncologyMelanoma
Checkpoint inhibitor seems safe and effective for patients with HIVOctober 23, 2018Immuno-oncologyMelanomaLung CancerHIV
Checkpoint inhibitor/TKI combo improves PFS of RCC over sunitinibOctober 22, 2018Genitourinary CancerImmuno-oncology
Researchers consider R/R ALL drugs in the first-line settingOctober 17, 2018Immuno-oncologyHematologic Malignancies
Researchers share Nobel Prize for cancer immunotherapy discoveriesOctober 1, 2018Immuno-oncologyMixed TopicsOncology
Nivolumab plus ipilimumab effective in melanoma brain metastasesAugust 27, 2018MelanomaImmuno-oncology
